Main Content

Core B – Omics and Gene-Editing Core

The Omics and Gene-Editing Core will provide MCHD investigators access to state-of-the-art omics technologies, including genomics [transcriptome sequencing (RNAseq), whole genome sequencing (WGS), amplicon sequencing (e.g., genotyping by sequencing], 16S/metagenomics, and epigenetic regulation (e.g., methylation)], targeted proteomics and metabolomics, and gene-editing technology. Core B will provide support to the centralized UMMC Molecular and Genomics Core Facility (MGCF). Core B will also provide researchers access to a comprehensive omics data collection pipeline and when integrated with Research Computing, Bioinformatics, and Biostatistics Core (Core C) will provide greater depth and insight into biological processes associated with investigator-initiated scientific questions involving the health and disease continuum.  Core B in collaboration with the MGCF, will enhance current infrastructure, including new high-throughput sequencing methods such as single cell sequencing, spatial transcriptomics, and long-read sequencing as well as develop new and innovative capabilities, including gene-editing. 

The MCHD has partnered with IDeA National Resource for Quantitative Proteomics to provide Discovery Proteomics Capabilities to our researchers. Dr. Allan Tackett will serve as a consultant for proteomic applications.

Alan Tackett, PhD University of Arkansas for Medical Sciences Deputy Director, Winthrop P. Rockefeller Cancer Institute Distinguished Professor of Biochemistry & Molecular Biology Scharlau Family Endowed Chair in Cancer Research Director, NIH IDeA National Resource for Quantitative Proteomics Director, NIH Center of Biomedical Research Excellence